l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)2D3-induced myeloid differentiation in acute myeloid leukemia cells

Ju Han Song, Eunchong Park, Myun Soo Kim, Kyung Min Cho, Su Ho Park, Arim Lee, Jiseon Song, Hyeoung Joon Kim, Jeong Tae Koh, Tae Sung Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment of acute myeloid leukemia (AML) largely depends on chemotherapy, but current regimens have been unsatisfactory for long-term remission. Although differentiation induction therapy utilizing 1,25(OH)2D3 (VD3) has shown great promise for the improvement of AML treatment efficacy, severe side effects caused by its supraphysiological dose limit its clinical application. Here we investigated the combinatorial effect of l-asparaginase (ASNase)-mediated amino acid depletion and the latent alternation of VD3 activity on the induction of myeloid differentiation. ASNase treatment enhanced VD3-driven phenotypic and functional differentiation of three-different AML cell lines into monocyte/macrophages, along with c-Myc downregulation. Using gene silencing with shRNA and a chemical blocker, we found that reduced c-Myc is a critical factor for improving VD3 efficacy. c-Myc-dependent inhibition of mTORC1 signaling and induction of autophagy were involved in the enhanced AML cell differentiation. In addition, in a postculture of AML cells after each treatment, ASNase supports the antileukemic effect of VD3 by inhibiting cell growth and inducing apoptosis. Finally, we confirmed that the administration of ASNase significantly improved VD3 efficacy in the prolongation of survival time in mice bearing tumor xenograft. Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.

Original languageEnglish
Pages (from-to)2364-2374
Number of pages11
JournalInternational Journal of Cancer
Volume140
Issue number10
DOIs
Publication statusPublished - 2017 May 15

Fingerprint

Asparaginase
Myeloid Cells
Acute Myeloid Leukemia
Down-Regulation
Therapeutics
Autophagy
Gene Silencing
Drug Combinations
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Small Interfering RNA
Monocytes
Cell Differentiation
Macrophages
Apoptosis
Amino Acids
Drug Therapy
Cell Line
Growth

Keywords

  • 1,25(OH)D
  • acute myeloid leukemia
  • autophagy
  • c-Myc
  • l-asparaginase
  • mTORC1
  • myeloid differentiation

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)2D3-induced myeloid differentiation in acute myeloid leukemia cells. / Song, Ju Han; Park, Eunchong; Kim, Myun Soo; Cho, Kyung Min; Park, Su Ho; Lee, Arim; Song, Jiseon; Kim, Hyeoung Joon; Koh, Jeong Tae; Kim, Tae Sung.

In: International Journal of Cancer, Vol. 140, No. 10, 15.05.2017, p. 2364-2374.

Research output: Contribution to journalArticle

Song, Ju Han ; Park, Eunchong ; Kim, Myun Soo ; Cho, Kyung Min ; Park, Su Ho ; Lee, Arim ; Song, Jiseon ; Kim, Hyeoung Joon ; Koh, Jeong Tae ; Kim, Tae Sung. / l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)2D3-induced myeloid differentiation in acute myeloid leukemia cells. In: International Journal of Cancer. 2017 ; Vol. 140, No. 10. pp. 2364-2374.
@article{79db5878ea0d48d3b006967085ceee69,
title = "l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)2D3-induced myeloid differentiation in acute myeloid leukemia cells",
abstract = "Treatment of acute myeloid leukemia (AML) largely depends on chemotherapy, but current regimens have been unsatisfactory for long-term remission. Although differentiation induction therapy utilizing 1,25(OH)2D3 (VD3) has shown great promise for the improvement of AML treatment efficacy, severe side effects caused by its supraphysiological dose limit its clinical application. Here we investigated the combinatorial effect of l-asparaginase (ASNase)-mediated amino acid depletion and the latent alternation of VD3 activity on the induction of myeloid differentiation. ASNase treatment enhanced VD3-driven phenotypic and functional differentiation of three-different AML cell lines into monocyte/macrophages, along with c-Myc downregulation. Using gene silencing with shRNA and a chemical blocker, we found that reduced c-Myc is a critical factor for improving VD3 efficacy. c-Myc-dependent inhibition of mTORC1 signaling and induction of autophagy were involved in the enhanced AML cell differentiation. In addition, in a postculture of AML cells after each treatment, ASNase supports the antileukemic effect of VD3 by inhibiting cell growth and inducing apoptosis. Finally, we confirmed that the administration of ASNase significantly improved VD3 efficacy in the prolongation of survival time in mice bearing tumor xenograft. Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.",
keywords = "1,25(OH)D, acute myeloid leukemia, autophagy, c-Myc, l-asparaginase, mTORC1, myeloid differentiation",
author = "Song, {Ju Han} and Eunchong Park and Kim, {Myun Soo} and Cho, {Kyung Min} and Park, {Su Ho} and Arim Lee and Jiseon Song and Kim, {Hyeoung Joon} and Koh, {Jeong Tae} and Kim, {Tae Sung}",
year = "2017",
month = "5",
day = "15",
doi = "10.1002/ijc.30662",
language = "English",
volume = "140",
pages = "2364--2374",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)2D3-induced myeloid differentiation in acute myeloid leukemia cells

AU - Song, Ju Han

AU - Park, Eunchong

AU - Kim, Myun Soo

AU - Cho, Kyung Min

AU - Park, Su Ho

AU - Lee, Arim

AU - Song, Jiseon

AU - Kim, Hyeoung Joon

AU - Koh, Jeong Tae

AU - Kim, Tae Sung

PY - 2017/5/15

Y1 - 2017/5/15

N2 - Treatment of acute myeloid leukemia (AML) largely depends on chemotherapy, but current regimens have been unsatisfactory for long-term remission. Although differentiation induction therapy utilizing 1,25(OH)2D3 (VD3) has shown great promise for the improvement of AML treatment efficacy, severe side effects caused by its supraphysiological dose limit its clinical application. Here we investigated the combinatorial effect of l-asparaginase (ASNase)-mediated amino acid depletion and the latent alternation of VD3 activity on the induction of myeloid differentiation. ASNase treatment enhanced VD3-driven phenotypic and functional differentiation of three-different AML cell lines into monocyte/macrophages, along with c-Myc downregulation. Using gene silencing with shRNA and a chemical blocker, we found that reduced c-Myc is a critical factor for improving VD3 efficacy. c-Myc-dependent inhibition of mTORC1 signaling and induction of autophagy were involved in the enhanced AML cell differentiation. In addition, in a postculture of AML cells after each treatment, ASNase supports the antileukemic effect of VD3 by inhibiting cell growth and inducing apoptosis. Finally, we confirmed that the administration of ASNase significantly improved VD3 efficacy in the prolongation of survival time in mice bearing tumor xenograft. Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.

AB - Treatment of acute myeloid leukemia (AML) largely depends on chemotherapy, but current regimens have been unsatisfactory for long-term remission. Although differentiation induction therapy utilizing 1,25(OH)2D3 (VD3) has shown great promise for the improvement of AML treatment efficacy, severe side effects caused by its supraphysiological dose limit its clinical application. Here we investigated the combinatorial effect of l-asparaginase (ASNase)-mediated amino acid depletion and the latent alternation of VD3 activity on the induction of myeloid differentiation. ASNase treatment enhanced VD3-driven phenotypic and functional differentiation of three-different AML cell lines into monocyte/macrophages, along with c-Myc downregulation. Using gene silencing with shRNA and a chemical blocker, we found that reduced c-Myc is a critical factor for improving VD3 efficacy. c-Myc-dependent inhibition of mTORC1 signaling and induction of autophagy were involved in the enhanced AML cell differentiation. In addition, in a postculture of AML cells after each treatment, ASNase supports the antileukemic effect of VD3 by inhibiting cell growth and inducing apoptosis. Finally, we confirmed that the administration of ASNase significantly improved VD3 efficacy in the prolongation of survival time in mice bearing tumor xenograft. Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.

KW - 1,25(OH)D

KW - acute myeloid leukemia

KW - autophagy

KW - c-Myc

KW - l-asparaginase

KW - mTORC1

KW - myeloid differentiation

UR - http://www.scopus.com/inward/record.url?scp=85015013521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015013521&partnerID=8YFLogxK

U2 - 10.1002/ijc.30662

DO - 10.1002/ijc.30662

M3 - Article

C2 - 28224619

AN - SCOPUS:85015013521

VL - 140

SP - 2364

EP - 2374

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -